Before & After

Consistent RESULTS WHEREVER PATIENTS
NEED IT

ZORYVE is for topical use only and not for ophthalmic, oral, or intravaginal use1,2

Not a steroid no boxed warning
Simple once-daily treatmentSimple once-daily treatment

For age 12+

For age 6+

FoamCream

ZORYVE FOAM. ONCE A DAY. ANYWHERE.

Review clinical trial photos of patients with plaque psoriasis treated with ZORYVE foam

Axilla

AxillaEar & scalpFaceLegScalp & neckScalpTrunk

ZORYVE FOAM. ONCE A DAY. ANYWHERE.

Review clinical trial photos of patients with plaque psoriasis treated with ZORYVE foam

Axilla3

AGE 60, MALE

Actual clinical trial patient

Baseline: B-IGA = 3

Baseline: B-IGA = 3

Week 2: B-IGA = 2
Week 4: B-IGA = 0
Week 8: B-IGA = 0

Ear & scalp3

AGE 65, MALE

Actual clinical trial patient

Baseline: S-IGA = 3

Baseline: S-IGA = 3

Week 2: S-IGA = 0
Week 4: S-IGA = 0
Week 8: S-IGA = 0

Face3

AGE 29, FEMALE

Actual clinical trial patient

Baseline: B-IGA = 3

Baseline: B-IGA = 3

Week 2: B-IGA = 2
Week 4: B-IGA = 2
Week 8: B-IGA = 1

Leg3

AGE 42, MALE

Actual clinical trial patient

Baseline: B-IGA = 3

Baseline: B-IGA = 3

Week 2: B-IGA = 3
Week 4: B-IGA = 3
Week 8: B-IGA = 1

AGE 56, MALE

Actual clinical trial patient

Baseline: B-IGA = 2

Baseline: B-IGA = 2

Week 2: B-IGA = 2
Week 4: B-IGA = 1
Week 8: B-IGA = 1

Scalp & neck3

AGE 56, FEMALE

Actual clinical trial patient

Baseline: S-IGA = 3

Baseline: S-IGA = 3

Week 2: S-IGA = 1
Week 4: S-IGA = 2
Week 8: S-IGA = 0

Scalp3

AGE 44, MALE

Actual clinical trial patient

Baseline: S-IGA = 3

Baseline: S-IGA = 3

Week 2: S-IGA = 3
Week 4: S-IGA = 2
Week 8: S-IGA = 1

AGE 56, MALE

Actual clinical trial patient

Baseline: S-IGA = 4

Baseline: S-IGA = 4

Week 2: S-IGA = 3
Week 4: S-IGA = 1
Week 8: S-IGA = 1

AGE 57, MALE

Actual clinical trial patient

Baseline: S-IGA = 4

Baseline: S-IGA = 4

Week 2: S-IGA = 3
Week 4: S-IGA = 2
Week 8: S-IGA = 1

AGE 61, FEMALE

Actual clinical trial patient

Baseline: S-IGA = 4

Baseline: S-IGA = 4

Week 2: S-IGA = 0
Week 4: S-IGA = 0
Week 8: S-IGA = 0

AGE 61, FEMALE

Actual clinical trial patient

Baseline: S-IGA = 4

Baseline: S-IGA = 4

Week 2: S-IGA = 0
Week 4: S-IGA = 0
Week 8: S-IGA = 0

Trunk3

AGE 59, FEMALE

Actual clinical trial patient

Baseline: B-IGA = 3

Baseline: B-IGA = 3

Week 2: B-IGA = 3
Week 4: B-IGA = 2
Week 8: B-IGA = 0

B-IGA Scale: 4 = Severe, 3 = Moderate,
2 = Mild, 1 = Almost Clear, 0 = Clear.
S-IGA Scale: 4 = Severe, 3 = Moderate,
2 = Mild, 1 = Almost Clear, 0 = Clear.

See
Efficacy Data

View
Safety Profile

Request a
Representative